Ensuring timely antibody delivery in the face of supply chain challenges - contact us for solutions

Goat F(ab')2 Anti-Rat IgG(H+L), Mouse ads-SPRD

Cat. No.:
3052-13
Goat F(ab')2 Anti-Rat IgG(H+L)-PE/CY5 (SPRD) antibody with minimal reactivity to mouse proteins for use in flow cytometry assays.
$297.00
Size Price (USD) Quantity
0.25 mg $297.00
More Information
Isotype Goat F(ab')2 IgG
Isotype Control Goat F(ab')2 IgG-SPRD
Specificity Reacts with the heavy and light chains of rat IgG and the light chains of rat IgM
Source Pepsin digest of Goat Anti-Rat IgG(H+L), Mouse ads (SB Cat. No. 3050)
Cross Adsorption Mouse immunoglobulins and pooled sera; may react with immunoglobulins from other species
Conjugate SPRD (R-phycoerythrin/Cyanine 5)
Buffer Formulation Phosphate buffered saline containing < 0.1% sodium azide and a stabilizer
Clonality Polyclonal
Concentration 0.25 mg/mL
Volume 1.0 mL
Recommended Storage 2-8°C; Avoid exposure to light; Do not freeze
Trademark Information Spectral Red® is a registered trademark of Southern Biotechnology Associates, Inc.
Spectral Red® is a PE/CY5 tandem conjugate
Cy® is a registered trademark of Global Life Sciences Solutions Germany GmbH
Applications Quality tested applications for relevant formats include -
ELISA
FLISA
Flow Cytometry 1-13

Other referenced applications for relevant formats include -
Immunohistochemistry-Frozen Sections 14-18
RRID Number AB_2795849

Certificate of Analysis Lookup

Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view


Need help with this product?
or call 800.722.2255
  1. 1. Yeatman CF 2nd, Jacobs-Helber SM, Mirmonsef P, Gillespie SR, Bouton LA, Collins HA, et al. Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)-4 and IL-10 induces mouse mast cell apoptosis. J Exp Med. 2000;192:1093-103. (FC)
  2. 2. Ishikawa S, Sato T, Abe M, Nagai S, Onai N, Yoneyama H, et al. Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med. 2001;193:1393-402. (FC)
  3. 3. Radu DL, Weksler ME, Bona CA. Maintenance of size and function of influenza virus hemagglutinin specific transgenic T-cell clone during life. J Cell Mol Med. 2001;5:388-96. (FC)
  4. 4. Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DA. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol. 2002;32:2255-63. (FC)
  5. 5. Xanthoulea S, Pasparakis M, Kousteni S, Brakebusch C, Wallach D, Bauer J, et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med. 2004;200:367-76. (FC)
  6. 6. Gillespie SR, DeMartino RR, Zhu J, Chong HJ, Ramirez C, Shelburne CP, et al. IL-10 inhibits FcεRI expression in mouse mast cells. J Immunol. 2004;172:3181-8. (FC)
  7. 7. Liu L, Xu Z, Fuhlbrigge RC, Peña-Cruz V, Lieberman J, Kupper TS. Vaccinia virus induces strong immunoregulatory cytokine production in healthy human epidermal keratinocytes: a novel strategy for immune evasion. J Virol. 2005;79:7363-70. (FC)
  8. 8. Lui O, Mak N, Leung K. Conjugated linoleic acid induces monocytic differentiation of murine myeloid leukemia cells. Int J Oncol. 2005;27:1737-43. (FC)
  9. 9. Balza E, Mortara L, Sassi F, Monteghirfo S, Carnemolla B, Castellani P, et al. Targeted delivery of tumor necrosis factor-α to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res. 2006;12:2575-82. (FC)
  10. 10. Despars G, O'Neill HC. Splenic endothelial cell lines support development of dendritic cells from bone marrow. Stem Cells. 2006;24:1496-504. (FC)
  11. 11. Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, Apostolidis C, et al. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res. 2007;67:1950-8. (FC)
  12. 12. Cheong C, Matos I, Choi J, Schauer JD, Dandamudi DB, Shrestha E, et al. New monoclonal anti-mouse DC-SIGN antibodies reactive with acetone-fixed cells. J Immunol Methods. 2010;360:66-75. (FC)
  13. 13. Saunderson SC, Dunn AC, Crocker PR, McLellan AD. CD169 mediates the capture of exosomes in spleen and lymph node. Blood. 2014;123:208-16. (FC)
  14. 14. Rennert PD, Browning JL, Hochman PS. Selective disruption of lymphotoxin ligands reveals a novel set of mucosal lymph nodes and unique effects on lymph node cellular organization. Int Immunol. 1997;9:1627-39. (IHC-FS)
  15. 15. Gołąb J, Wilczyński G, Zagożdżon R, Stokłosa T, Dąbrowska A, Rybczyńska J, et al. Potentiation of the anti-tumour effects of Photofrin®-based photodynamic therapy by localized treatment with G-CSF. Br J Cancer. 2000;82:1485-91. (IHC-FS)
  16. 16. Wuttge DM, Zhou X, Sheikine Y, Wågsäter D, Stemme V, Hedin U, et al. CXCL16/SR-PSOX is an interferon-γ-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2004;24:750-5. (IHC-FS)
  17. 17. Sun Y, Blink SE, Chen JH, Fu Y. Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling. J Immunol. 2005;175:884-90. (IHC-FS)
  18. 18. Martinez-Torres A, Quiney C, Attout T, Boullet H, Herbi L, Vela L, et al. CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans. PLoS Med. 2015;12(3):e1001796. (IHC-FS)
See All References